2535E07B-4CB8-4608-87F3-D8D6371B8862
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.672
- MYC_TARGETS_V1+0.582
- E2F_TARGETS+0.557
- G2M_CHECKPOINT+0.543
- DNA_REPAIR+0.459
- UNFOLDED_PROTEIN_RESPONSE+0.438
- WNT_BETA_CATENIN_SIGNALING+0.423
- OXIDATIVE_PHOSPHORYLATION+0.367
- ANGIOGENESIS+0.322
- MITOTIC_SPINDLE+0.256
Top 10 suppressed
- KRAS_SIGNALING_DN-0.432
- BILE_ACID_METABOLISM-0.311
- INFLAMMATORY_RESPONSE-0.184
- ESTROGEN_RESPONSE_LATE-0.148
- MYOGENESIS-0.139
- PANCREAS_BETA_CELLS-0.117
- TNFA_SIGNALING_VIA_NFKB-0.117
- SPERMATOGENESIS-0.116
- COAGULATION-0.099
- XENOBIOTIC_METABOLISM-0.091
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934902 | — | — | 0.912 |
| 2 | FB7673F7-FF7F-4C3C-A8C6-9C11C6BB71D5 | — | — | 0.911 |
| 3 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.902 |
| 4 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.898 |
| 5 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.895 |
| 6 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.892 |
| 7 | SRR934719 | — | — | 0.888 |
| 8 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.886 |
| 9 | 67719D37-8CC2-42B5-AF44-6D5AC258FDB1 | — | — | 0.872 |
| 10 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.672 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.582 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.557 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.543 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.459 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.438 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.423 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.367 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.322 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.256 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.223 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.205 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.192 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.184 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.157 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.106 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.104 | Inavolisib | — uncovered |